Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol
Marketing
Arrowhead's plozasiran could reach $700M-plus in sales: report
The drug has shown promise in reducing triglycerides and the protein APOC3, meaning it could be used to treat many forms of dyslipidemia.
Andrea Park
Apr 16, 2024 3:05pm
Dyslipidemia space to 'undergo a massive shake-up': report
Aug 10, 2023 10:30am
FDA rebukes small biotech Althera for promotional claims
Jun 13, 2022 5:56am
Amgen dealt another blow in closely watched PCSK9 patent case
Jun 22, 2021 10:40am